| 04 December 2018 |
Probiodrug to present at Antibody Engineering & Therapeutics in December 2018 |
| 29 November 2018 |
Probiodrug AG Reports Third Quarter 2018 Business Update |
| 22 November 2018 |
Probiodrug AG to Publish its Third Quarter 2018 Business Update on November 29, 2018 |
| 29 October 2018 |
Probiodrug to Attend and Present at International Conferences in November 2018 |
| 16 October 2018 |
Probiodrug publishes SAPHIR data in peer reviewed journal |
| 15 October 2018 |
Probiodrug AG: Loss announcement according to §92 paragraph 1 of the German Stock Corporation Act |
| 09 October 2018 |
Probiodrug to attend International Conferences in October 2018 |
| 05 October 2018 |
Probiodrug Reports Management Changes |
| 04 September 2018 |
Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy |
| 30 August 2018 |
Probiodrug Reports Financial Results for H1 2018 and Corporate Update |
| 23 August 2018 |
Probiodrug AG to Publish First Half 2018 Results on August 30, 2018 |
| 22 June 2018 |
Ordinary General Meeting of Shareholders of Probiodrug AG |
| 29 May 2018 |
Probiodrug to attend and present at the BIO International Convention in June 2018 |
| 25 May 2018 |
Probiodrug updated Privacy Policy |
| 15 May 2018 |
Probiodrug AG reports First Quarter 2018 Business Update |
| 09 May 2018 |
Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 21 June 2018 |
| 08 May 2018 |
Probiodrug positioning its pGlu-Abeta Antibody in the field of Abeta antibodies |
| 08 May 2018 |
Probiodrug AG to Publish its First Quarter 2018 Business Update on 15 May 2018 |
| 04 May 2018 |
Probiodrug to attend and present at International Conferences in May 2018 |
| 23 April 2018 |
Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer |
| 10 April 2018 |
Probiodrug AG: Probiodrug to attend and present at International Conferences in April 2018 |
| 03 April 2018 |
Probiodrug reports full year 2017 financial results |
| 27 March 2018 |
Probiodrug AG to Publish its Full Year 2017 Results on 3 April 2018 |
| 16 March 2018 |
Probiodrug to present at 255th ACS National Meeting & Exposition |
| 27 February 2018 |
Probiodrug to attend and present at international conferences in March 2018 |
| 23 January 2018 |
Probiodrug AG: Probiodrug to attend and present at upcoming international conferences |
| 14 December 2017 |
Probiodrug AG: Probiodrug to attend and present at international conferences in January 2018 |
| 14 December 2017 |
Probiodrug AG: Probiodrug to attend and present at international conferences in January 2018 |
| 05 December 2017 |
Probiodrug AG: Probiodrug and Crossbeta Biosciences extend their strategic partnership in the field of Alzheimer's disease biomarkers |
| 30 November 2017 |
CORRECTION: Probiodrug AG: Probiodrug reports Third Quarter 2017 Business Update |
| 30 November 2017 |
Probiodrug AG: Probiodrug reports Third Quarter 2017 Business Update |
| 23 November 2017 |
Probiodrug : Probiodrug AG to Publish its Third Quarter 2017 Business Update on 30 November 2017 |
| 26 October 2017 |
Probiodrug to Present Data from its Phase 2a SAPHIR Study at International Alzheimer's Disease Conference |
| 24 October 2017 |
Probiodrug to present at Life Sciences Conferences in November |
| 16 October 2017 |
Probiodrug initiates Phase 2b core program of PQ912 and details further strategy |
| 28 September 2017 |
Probiodrug to present at Life Sciences Conferences in October 2017 |
| 31 August 2017 |
Probiodrug reports financial results for H1 2017 and corporate update |
| 30 August 2017 |
Probiodrug to attend and present at International Conferences in September 2017 |
| 29 August 2017 |
Unique binding mode of PBD-C06 to pGlu-Abeta peptides identified |
| 24 August 2017 |
Probiodrug AG to Publish First Half 2017 Results on 31 August 2017 |
| 14 June 2017 |
Ordinary General Meeting of Shareholders of Probiodrug AG |
| 11 June 2017 |
Probiodrug announces encouraging results of the Phase 2a SAPHIR Study |
| 30 May 2017 |
Probiodrug to present and attend at International Conferences in June 2017 |
| 16 May 2017 |
Probiodrug AG Announces Acceptance of PQ912 Pharmacology Paper by Peer Reviewed Journal |
| 12 May 2017 |
Probiodrug AG reports First Quarter 2017 Business Update |
| 05 May 2017 |
Probiodrug AG to Publish its First Quarter 2017 Business Update on 12 May 2017 |
| 02 May 2017 |
Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 13 June 2017 |
| 25 April 2017 |
Probiodrug to attend and present at International Conferences in May 2017 |
| 10 April 2017 |
Probiodrug to present at Huntington's Disease Therapeutics Conference |
| 07 April 2017 |
Last Patient Last Visit (LPLV) reached in the SAPHIR Study |
| 03 April 2017 |
Probiodrug to attend International Conferences in April 2017 |
| 30 March 2017 |
Probiodrug reports full year 2016 financial results |
| 28 March 2017 |
Probiodrug to present at Alzheimer's and Parkinson's Diseases Congress |
| 23 March 2017 |
Probiodrug AG to Publish its Full Year 2016 Results on 30 March 2017 |
| 06 March 2017 |
Probiodrug to attend and present at International Conferences in March 2017 |
| 02 February 2017 |
Probiodrug to attend and present at International Conferences in February 2017 |
| 09 January 2017 |
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients |
| 04 January 2017 |
Probiodrug to attend International Conferences in January 2017 |
| 08 December 2016 |
Probiodrug: Innovative Phase II study design of Glutaminylcyclase Inhibitor PQ912 in early Alzheimer's disease |
| 16 November 2016 |
Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer's mouse model |
| 14 November 2016 |
Probiodrug to attend US Life Sciences Conferences in November 2016 |
| 10 November 2016 |
Probiodrug reports Third Quarter 2016 Business Update |
| 03 November 2016 |
Probiodrug AG to Publish its Third Quarter 2016 Business Update on 10 November 2016 |
| 27 October 2016 |
Probiodrug to present at European Life Sciences Conferences |
| 11 October 2016 |
Probiodrug to present at US and Japanese Life Science Conferences in October 2016 |
| 06 October 2016 |
Probiodrug announces pricing of a EUR 14.9 million accelerated bookbuild offering of new shares |
| 05 October 2016 |
Probiodrug launches capital increase by means of an accelerated bookbuild offering |
| 13 September 2016 |
Combination therapy with Glutaminyl Cyclase (QC) inhibitor PQ912 & pGlu-Abeta specific antibody PBD-C06 shows clear additive effects in reducing pGlu-Abeta as well as Abeta in Alzheimer-mouse model |
| 07 September 2016 |
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in an inflammation animal model |
| 30 August 2016 |
Probiodrug reports financial results for H1 2016 |
| 25 August 2016 |
Probiodrug to present at US Life Sciences Conferences |
| 23 August 2016 |
Probiodrug AG to Publish First Half 2016 Results on 30 August 2016 |
| 16 August 2016 |
Probiodrug to present at European Life Sciences Conferences |
| 12 August 2016 |
Probiodrug Announces Changes to the Supervisory Board and Executive Management |
| 30 June 2016 |
Probiodrug and Crossbeta Biosciences enter into a strategic partnership in the field of Alzheimer's disease biomarkers |
| 09 June 2016 |
Probiodrug:Two key patents on Glutaminyl Cyclase (QC) inhibition for the treatment of Alzheimer's disease (AD) granted in Japan |
| 27 May 2016 |
Probiodrug to Attend and Present at International Conferences in June 2016 |
| 20 May 2016 |
Ordinary General Meeting of Shareholders of Probiodrug AG |
| 12 May 2016 |
Probiodrug reports First Quarter 2016 Business Update |
| 11 May 2016 |
Probiodrug to Present at the 1st Meeting of The Society for CSF analysis and Clinical Neurochemistry |
| 04 May 2016 |
Probiodrug AG to Publish its First Quarter 2016 Business Update on May 12, 2016 |
| 03 May 2016 |
Probiodrug to Attend and Present at European Conferences in May 2016 |
| 05 April 2016 |
Probiodrug to hold its Ordinary General Meeting of Shareholders on May 19, 2016 |
| 15 March 2016 |
Probiodrug Reports Full Year 2015 Financial Results |
| 09 March 2016 |
Probiodrug's pGlu-Abeta Approaches being presented at 14th AAT Symposium on Advances in Alzheimer Therapy |
| 07 March 2016 |
Probiodrug AG to Publish its Full Year 2015 Results on March 15, 2016 |
| 22 February 2016 |
Probiodrug to Attend and Present at European Conferences in March 2016 |
| 28 January 2016 |
Probiodrug to Attend and Present at European and US Conferences in February 2016 |
| 11 January 2016 |
Key patents granted for Probiodrug's pGlu-Abeta targeting monoclonal antibody program for the treatment of Alzheimer's disease |
| 05 January 2016 |
Probiodrug to attend International Conferences in January 2016 |
| 15 December 2015 |
Probiodrug announces publication of initial PQ912 clinical data demonstrating inhibition of glutaminyl cyclase |
| 20 November 2015 |
Probiodrug to Attend and Present at International Conferences in November and December 2015 |
| 19 November 2015 |
Probiodrug reports Third Quarter 2015 Business Update |
| 12 November 2015 |
Probiodrug AG to Publish its Third Quarter 2015 Business Update on November 19, 2015 |
| 05 November 2015 |
Probiodrug announces pricing of a EUR 13.5 million private placement of new shares |
| 28 October 2015 |
Probiodrug to attend and present at European Conferences in November 2015 |
| 19 October 2015 |
Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody at Neuroscience 2015, Chicago |
| 15 October 2015 |
Probiodrug to present at US and Japanese Conferences |
| 12 October 2015 |
Probiodrug collaborates with the Paul-Flechsig-Institute for Brain Research, Leipzig University, Germany |
| 07 October 2015 |
Probiodrug signs agreement with Rentschler for manufacture of its pGlu-Abeta targeting antibody PBD-C06 |
| 08 September 2015 |
Probiodrug to attend and present at US Life Science Conferences |
| 03 September 2015 |
Probiodrug to present at European Life Sciences Conferences in September 2015 |
| 01 September 2015 |
Probiodrug Licenses the TBA 2.1 Transgenic Alzheimer's Disease Mouse Model to QPS Austria Neuropharmacology |
| 27 August 2015 |
Probiodrug reports financial results for H1 2015 |
| 24 August 2015 |
Probiodrug to present at the International Conference on Brain Disorders and Therapeutics in London, UK |
| 20 August 2015 |
Probiodrug AG to Publish First Half 2015 Results on 27 August, 2015 |
| 13 July 2015 |
Probiodrug Funds Brigham and Women's Hospital Research into pyroglutamate-Abeta for the Treatment of Alzheimer's Disease |
| 12 June 2015 |
Probiodrug receives 2015 European Mediscience Award for Best Technology |
| 10 June 2015 |
Probiodrug: Annual General Meeting and Election of New Supervisory Board members |
| 29 May 2015 |
Probiodrug to present at the Jefferies Healthcare Conference and BIO International Convention |
| 18 May 2015 |
Probiodrug to present at Bio€quity Europe 2015 in Vienna |
| 13 May 2015 |
Probiodrug reports First Quarter 2015 Business Update |
| 08 May 2015 |
Probiodrug to hold its Annual Shareholders Meeting on June 10, 2015 |
| 06 May 2015 |
Probiodrug AG to publish its First Quarter 2015 Business Update on May 13, 2015 |
| 05 May 2015 |
Probiodrug to Present at Drug Design & Medicinal Chemistry Conference 2015 |
| 23 April 2015 |
Probiodrug: Key patents on Glutaminyl Cyclase (QC) inhibition for the treatment of Alzheimer's disease granted in Japan |
| 31 March 2015 |
Probiodrug reports full year 2014 financial results |
| 20 March 2015 |
Probiodrug to present at Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM 2015) |
| 18 March 2015 |
Probiodrug AG to publish its 2014 Annual Report on March 31, 2015 |
| 09 March 2015 |
Probiodrug announces enrolment of first patient in Phase 2 Study of novel Treatment for Alzheimer's disease |
| 03 March 2015 |
Probiodrug: Data on Glutaminyl Cyclases (QCs) in its relation to Alzheimer's Disease (AD) published in Acta Neuropathologica |
| 25 February 2015 |
Probiodrug to present at European Life Sciences Conferences |
| 09 February 2015 |
Probiodrug to Present at Drug Discovery USA 2015 |
| 04 February 2015 |
Probiodrug to present at 17th Annual BIO CEO & Investor Conference, New York City |
| 17 November 2014 |
Probiodrug to present data on therapeutic concept of targeting pyro-Glu Abeta and its frontrunner QC-inhibitor PQ912 at International Alzheimer Conferences |
| 14 November 2014 |
Probiodrug: Capital increase from authorized capital in connection with the Greenshoe option has been completed |
| 12 November 2014 |
Probiodrug :Probiodrug announces the exercise of the Greenshoe Option, increasing the gross proceeds of the Offer to EUR 23.2 million |
| 31 October 2014 |
Dr Inge Lues joins Probiodrug Management Board as Chief Development Officer |
| 29 October 2014 |
Probiodrug: Increase in share capital |
| 23 October 2014 |
Probiodrug raises €22.5 million in successful Initial Public Offering and listing on Euronext Amsterdam |